agement of meningococcal disease requires antimicrobial drug treatment of patients with β-lactams and chemo-prophylaxis of contact persons with rifampin. High-level resistance to rifampin (MIC>32 mg/L) in Neisseria meningitidis is provoked by mutations (most frequently at the residue His 552) in the rpoB gene encoding the β subunit of RNA poly-merase (1,2). Resistance may lead to chemoprophylaxis failure and must be rapidly detected (3). Concerns have been raised about the clonal spread of resistant isolates (1); however
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.